Table 3 Summary of docetaxel pharmacokinetics

From: A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours

Visit

Patient

T max (h)

Cmax(ng ml−1)

AUClast(h*ng ml−1)

AUCINF(h*ng ml−1)

Cl (L h−1)

Vz (L)

Half-life (h)

MRT INF (h)

C1D1

N

43

43

43

43

43

43

43

43

 

Mean

0.19

799.12

1203.79

1530.81

143.66

2993.46

14.89

15.23

 

SE

0.02

146.59

235.49

270.84

10.98

273.91

1.12

1.65

 

CV%

56.1

120.3

128.3

116

50.1

60

49.3

70.9

C2D1

N

35

35

35

35

35

35

35

35

 

Mean

0.19

538.86

850.85

1106.26

154.1

2691.45

13.14

13.89

 

SE

0.02

60.66

88.15

127.4

15.23

235.19

0.87

1.08

 

CV%

48.1

66.6

61.3

68.1

58.5

51.7

39

46.1

  1. Abbreviations: AUC=area under the curve; C=cycle; Cl=clearance; CV=coefficient of variance; INF=infinity; D=day; MRT=mean resonance time; SE=standard error; Vz=volume of distribution.
Back to article page